Harvoni
Indicated for chronic hepatitis c to support viral clearance.
Strengths: 90/400mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Hepatitis C Antiviral
- Pharmacological class
NS5A Inhibitor; NS5B Polymerase Inhibitor
- Contraindications
hypersensitivity to ledipasvir; hypersensitivity to sofosbuvir
- Minor side effects
fatigue; headache
- Moderate side effects
insomnia; nausea
- Serious side effects
hypersensitivity — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
Indicated for chronic hepatitis c to support viral clearance.
- Prescription status
POM
- Manufacturer
Gilead Sciences
- Onset Time
1–2 weeks
- Duration
12–24 weeks
- Storage instructions
Store below 30°C in the original container.
- Drug interactions
amiodarone; rifampicin
- Age restrictions
For adult use.
Mechanism of action
A combination of a direct-acting antiviral drug that inhibits NS5A and an NS5B polymerase inhibitor, used to stop the hepatitis C virus from reproducing in the body.
Pregnancy and breastfeeding
Pregnancy: Use only if the potential benefit justifies potential risk. Breastfeeding: Advise that the excretion of components into human milk is unknown.
Harvoni
Indicated for chronic hepatitis c to support viral clearance.
Editorial Notes
- Active ingredient(s): Ledipasvir, Sofosbuvir
- Listed indication(s): Chronic Hepatitis C
Available option
- 28 tablets - 90/400 mg864-90-400-mg-6368